CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables.

Published

Journal Article

The CDKN2A gene encodes a cyclin-dependent kinase inhibitor, p16, which promotes cell cycle arrest. Methylation of the promoter region of the gene transcriptionally inactivates the gene. We have analyzed the methylation status of the promoter region of the CDKN2A gene in gastric adenocarcinomas using methylation-specific polymerase chain reaction. We also examined the tumors by immunohistochemistry for p16 protein. Of 114 gastric adenocarcinomas analyzed by immunohistochemistry, 34 cases (30%) were negative for p16 protein. Twenty-four of these 34 cases (71%) had methylation of the promoter region of the CDKN2A gene. Methylation of the promoter was strongly associated with loss of p16 protein by immunohistochemistry (P <0.0001). Neither stage, grade, anatomic site, or histologic subtype of the tumor nor age, gender, ethnic origin, or survival time of the patient were significantly different between the groups characterized by tumors with and without methylation. CDKN2A promoter methylation was not significantly associated with microsatellite instability.

Full Text

Duke Authors

Cited Authors

  • Vo, QN; Geradts, J; Boudreau, DA; Bravo, JC; Schneider, BG

Published Date

  • December 2002

Published In

Volume / Issue

  • 33 / 12

Start / End Page

  • 1200 - 1204

PubMed ID

  • 12514789

Pubmed Central ID

  • 12514789

International Standard Serial Number (ISSN)

  • 0046-8177

Digital Object Identifier (DOI)

  • 10.1053/hupa.2002.130108

Language

  • eng

Conference Location

  • United States